Effects of captopril on blood pressure and respiratory function compared to verapamil in patients with hypertension and asthma.
Seventeen adult patients with moderate and stable bronchial asthma and established essential hypertension (WHO I or II) were evaluated in a randomized, double-blind, crossover study of the effects of captopril (50-100 mg/day) and verapamil (160-240 mg/day) on blood pressure, orthostatic reactions, respiratory function, and asthmatic symptoms. The effect of both drugs on blood pressure was significant. Blood pressure (mean of 161/98 mm Hg initially) decreased to a mean of 147/90 and 160/91 mm Hg on captopril and verapamil, respectively, with normal orthostatic changes. There were no significant differences in forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), maximal expiratory flow at 50% of FVC (MEF50), or peak expiratory flow (PEF) measurements at the end of each treatment period. The subjective severity of asthma did not change significantly during the trial. No significant cough symptoms were reported on captopril.
Department of Pulmonary Medicine, Helsinki University Central Hospital, Finland.
H
H
Riska
A R
AR
Sovijärvi
A
A
Ahonen
Y
Y
Salorinne
S
S
Sundberg
B
B
Stenius-Aarniala
D000368:Aged; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects*; D002216:Captopril / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate; D012119:Respiration / Q000187:drug effects*; D012129:Respiratory Function Tests; D014700:Verapamil / Q000009:adverse effects / Q000627:therapeutic use*; D014797:Vital Capacity
D002216:Captopril; D014700:Verapamil